PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy by Jani, Jitesh P, Arcari, Joel, Bernardo, Vincent, Bhattacharya, Samit K, Briere, David, Cohen, Bruce D, Coleman, Kevin, Christensen, James G, Emerson, Erling O, Jakowski, Amy, Hook, Kenneth, Los, Gerrit, Moyer, James D, Pruimboom-Brees, Ingrid, Pustilnik, Leslie, Rossi, Ann Marie, Steyn, Stefan J, Su, Chunyan, Tsaparikos, Konstantinos, Wishka, Donn, Yoon, Kwansik, Jakubczak, John L

Get full text

Discovery and pharmacologic characterization of CP-724,714, a selective ErbB2 tyrosine kinase inhibitor by JANI, Jitesh P, FINN, Richard S, MORRIS, Joel, MOYER, James D, PUSTILNIK, Leslie R, RAFIDI, Kristina, RALSTON, Sherry, ROSSI, Ann Marie K, STEYN, Stefanus J, WAGNER, Larry, WINTER, Steven M, BHATTACHARYA, Samit K, CAMPBELL, Mary, COLEMAN, Kevin G, CONNELL, Richard D, CURRIER, Nicolas, EMERSON, Erling O, FLOYD, Eugenia, HARRIMAN, Shawn, KATH, John C

Get full text

Abstract 5466: The Mdm2 inhibitor, NVP-CGM097, in combination with the BRAF inhibitor NVP-LGX818 elicits synergistic antitumor effects in melanoma by Wang, Hui Qin, Zubrowski, Matthew, Emerson, Erling, Pradhan, Elina, Jeay, Sébastien, Wiesmann, Marion, Caponigro, Giordano, Wuerthner, Jens, Schlegel, Robert, Cao, Z. Alexander, Huang, Alan, Halilovic, Ensar

Get full text

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy by Beebe, Jean S, Jani, Jitesh P, Knauth, Elisabeth, Goodwin, Peter, Higdon, Carla, Rossi, Ann Marie, Emerson, Erling, Finkelstein, Martin, Floyd, Eugenia, Harriman, Shawn, Atherton, Jim, Hillerman, Steve, Soderstrom, Cathy, Kou, Kou, Gant, Tom, Noe, Mark C, Foster, Barb, Rastinejad, Farzan, Marx, Matthew A, Schaeffer, Tracey, Whalen, Pamela M, Roberts, W Gregory

Get full text

Abstract A86: Design, synthesis, and SAR of focal adhesion kinase (FAK) inhibitors by Roberts, Walter Gregory, Berliner, Martin, Coleman, Kevin, Emerson, Erling, Griffor, Matt, Hulford, Catherine, Jani, Jitesh, Kath, John, LaGreca, Susan, Lin, Jing, Lorenzen, Marianne J., Marr, Eric, Martinez-Alsina, Luis, Patel, Nandini, Richter, Daniel, Roberts, Erika, Autry, Christopher, Ung, Ethan, Felix, Vajdos, Vetelino, Beth, Wessel, Matthew, Whalen, Pamela, Xu, Huiping, Yao, Lili

Get full text

The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells by BARBACCI, E. Gabriella, PUSTILNIK, Leslie R, KATH, John C, ZHENGYU LIU, MOYER, James D, ROSSI, Ann Marie K, EMERSON, Erling, MILLER, Penny E, BOSCOE, Brian P, COX, Eric D, IWATA, Kenneth K, JANI, Jitesh P, PROVONCHA, Kathleen

Get full text

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587) by DIONNE, C. A, CAMORATTO, A. M, GEORGE, D, ISAACS, J. T, JANI, J. P, EMERSON, E, NEFF, N, VAUGHT, J. L, MURAKATA, C, DJAKIEW, D, LAMB, J, BOVA, S

Get full text

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy1 by BEEBE, Jean S, JANI, Jitesh P, ATHERTON, Jim, HILLERMAN, Steve, SODERSTROM, Cathy, KOU KOU, GANT, Tom, NOE, Mark C, FOSTER, Barb, RASTINEJAD, Farzan, MARX, Matthew A, SCHAEFFER, Tracey, KNAUTH, Elisabeth, WHALEN, Pamela M, ROBERTS, W. Gregory, GOODWIN, Peter, HIGDON, Carla, ROSSI, Ann Marie, EMERSON, Erling, FINKELSTEIN, Martin, FLOYD, Eugenia, HARRIMAN, Shawn

Get full text

Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C by Singh, Shivendra V., Xu, Bing H., Gupta, Vicram, Emerson, Erling O., Zaren, Howard A., Jani, Jitesh P.

Get full text